Journal
ONCOIMMUNOLOGY
Volume 4, Issue 7, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2015.1011524
Keywords
cutaneous T-cell lymphoma; chemokine receptor; mogamulizumab; mycosis fungoides; monoclonal antibody; regulatory T cells; Sezary syndrome; targeted therapy
Categories
Ask authors/readers for more resources
The CC chemokine receptor 4 (CCR4) is highly expressed on type 2 helper T cells and regulatory T (Treg) cells. Mogamulizumab, an anti-CCR4 antibody, reduces the numbers of CCR4(+) malignant T cells and CCR4(+) Treg cells in cutaneous T-cell lymphoma. Depleting Treg cells by targeting CCR4 has great potential in cancer immunotherapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
